Research
Dr. Hatlen’s research interests focus on HIV and COVID-19. Dr. Hatlen is an active member-in-training of the Advancing Clinical Therapeutics Globally (ACTG), subcommittee of ARTS transformative science group, as well as a contributor to the NIH Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (subcommittees: Mycobacterium avium complex, cryptosporidiosis and microsporidiosis).
As a clinical investigator, he is involved in both NIH and industry related trials. Currently, he services the role of Primary Investigator in a phase II/III, RCT, for ART naïve and experienced PWH evaluating a novel once weekly option. Additionally, he is involved as a co/sub-investigator in ongoing studies evaluating long-acting ART regimens for PWH and challenges in oral ART adherence, Hepatitis B cure in PHW, evaluating therapies to reduce comorbidities in PWH, other treatment trials for PWH, and long acting PrEP. He is interested in evaluating novel ways to improve retention and suppression.
Currently, Dr. Hatlen is the vice chair of an upcoming ACTG trial, A5431, a novel long-acting ART combination in PWH failing oral therapy with underlying resistance. Regarding COVID-19, he is actively involved in leadership roles related to vaccine prevention, therapeutics for outpatient and inpatient setting, and evaluating clinical/genomic predictors for long-term prognostics. He has completed inpatient cohort reviews on outcomes and management of COVID-19 in a safety net municipal system.
Dr. Hatlen serves as the site Primary Investigator for inpatient COVID therapeutic trials at Harbor-UCLA. Initially pharmaceutical sponsored, he and the team have now transitioned to research through the NIH as a site for ACTIV-3 trials and now transitioned to the STRIVE platform. Overall, Dr. Hatlen has been involved in multiple publications related to such outcomes.
Biography
Dr. Timothy Hatlen is an Assistant Clinical Professor, serving as junior faculty at Harbor-UCLA Division of HIV Medicine and The Lundquist Institute for Biomedical Innovation in the Division of HIV. His core job responsibility is to direct patient care on the inpatient/outpatient consult teaching service of Infectious Diseases and HIV at Harbor-UCLA Medical Center as well my as provide primary care for a panel of patients with HIV at a satellite outpatient clinic, Long Beach Comprehensive Health Center. Additionally, Dr. Hatlen is the Program Director for the Adult Infectious Disease fellowship at Harbor-UCLA.